Skip to main content

Table 1 Demographic and clinical characteristics of cervical cancer patients (n = 50)

From: Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa

Characteristic n (%)
Age (years)
  ≤ 40 8 (16)
 41–50 8 (16)
 51–60 21 (42)
  > 60 13 (26)
Ethnicity
 Black African 44 (88)
 Indian/Asian 3 (6)
 Coloured 3 (6)
Stage of cancer
 I A 1 (2)
 II A 7 (14)
 II B 25 (50)
 III A 4 (8)
 III B 13 (26)
Comorbidities
 None 11 (22)
 HIV infection only 20 (40)
 Hypertension only 10 (20)
 Diabetes only 2 (4)
 Diabetes and hypertension 4 (8)
 HIV and hypertension 2 (4)
 HIV and Epilepsy 1 (2)
Cisplatin Dosage
 Mid-cycle (150 mg/m2) 50 (100)
 One-month post-treatment follow up  
 150 mg/m2 8 (16)
 200 mg/m2 14 (28)
 250 mg/m2 10 (20)
 300 mg/m2 18 (36)